Skip to main content
KRAS mutation testing remains limited, although it is growing. Sotorasib is the first KRAS inhibitor to be FDA approved for KRAS mutation–positive, metastatic NSCLC, making it more important than ever before for physicians to consider testing for KRAS mutations. Read More ›

Patients with NSCLC and KRAS mutation treated with ICI monotherapy show longer OS and longer PFS when compared with patients with non-KRAS NSCLC. Read More ›

The COVID-19 pandemic continues to impact healthcare across the globe. We are yet to see the full effect of the COVID-19 pandemic on patients with cancer, including patients with non–small-cell lung cancer (NSCLC). With the recent emergence of the COVID-19 Omicron variant, we expect this impact on healthcare and cancer care to continue. The Year in Review series is an important tool to reach audiences and provide timely and relevant information on treatment advances in the oncology setting. Read More ›

Barriers to use of digitalized healthcare platforms in elderly patients must be overcome before these tools can be used effectively within this patient group. Telemonitoring has shown to be beneficial among elderly patients and may be a viable digitalized healthcare tool for this growing group of patients with cancer. Read More ›

NSCLC patients with advanced KRASG12C maintained their quality of life and physical function while receiving sotorasib treatment, with manageable side effects. Read More ›

NGS is becoming increasingly prevalent in cancer treatment. The barriers to NGS testing within the oncology community must be viewed as a priority and must be overcome with help from all stakeholders in the oncologic field. Read More ›

Healthcare personnel’s understanding of patients’ feelings and empathy, along with steps to improve patients’ resilience, are seen as the most important factors in maintaining patients with cancer’s mental state, including maintaining their levels of anxiety and depression. Read More ›

Sotorasib achieved a response rate across all trial subgroups in the recently announced research results of the phase 2 CodeBreaK 100 trial. Read More ›

Patients with NSCLC who are positive for KRASG12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›

Diabetes is associated with increased risk for a number of cancers, including NSCLC. Patients with hyperglycemic NSCLC treated with pembrolizumab show poorer PFS and earlier tumor progression when compared with NSCLC patients with normal blood glucose levels. Read More ›

Page 3 of 16